Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Meldonium and Mirabegron (YM-178) — mechanism, dosing, side effects, legal status, and pricing.
Meldonium (Mildronate) is a small-molecule carnitine-biosynthesis inhibitor and anti-ischemic metabolic modulator — not a peptide. It is an approved prescription drug for cardiovascular indications in several ex-Soviet states but is not FDA- or EMA-approved, and it is WADA-prohibited (added January 2016, of Sharapova notoriety). It is also sold as a gray-market research chemical.
Mirabegron is a non-peptide, small-molecule selective β3-adrenergic receptor agonist FDA-approved in 2012 for overactive bladder at 25–50 mg/day oral dosing. It is also sold as unregulated 'research use only' powder by fine-chemical vendors, despite being a prescription pharmaceutical. Investigational metabolic research has used a supratherapeutic 100 mg/day dose to study brown adipose tissue activation—an off-label, non-approved use. Mirabegron is pharmacologically distinct from WADA-prohibited β2-agonists, though its it is not on the WADA Prohibited List (only beta-2 agonists are prohibited, Category S3).
Meldonium
Mirabegron (YM-178)
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Meldonium
No pricing data yet.
Check Meldonium prices →Mirabegron (YM-178)
No pricing data yet.
Check Mirabegron (YM-178) prices →COA corpus from Disclosed Labs — independently tested batches only.
Meldonium
2
COAs
99.9%
Avg purity
2
Labs
Mirabegron (YM-178)
1
COAs
99.8%
Avg purity
1
Labs
In rat ischemia-reperfusion models, meldonium (100–200 mg/kg) reduced myocardial infarct size ~30% and protected liver, brain, and endothelial function. In humans it is used clinically (in approving markets) for chronic heart failure and angina at 500 mg twice daily, but there is no FDA/EMA-registered pivotal efficacy trial. Urinary detection persists for weeks-to-months, central to doping cases. Not FDA/EMA-approved; not a peptide.
Mirabegron is an FDA-approved drug with extensive human data, not a novel research chemical. Approved adult dosing is 25 mg once daily, increased to 50 mg after 4–8 weeks for overactive bladder. A registered clinical trial (NCT04823442) used 100 mg/day for 4 weeks in 14 healthy women, reporting increased brown adipose tissue activity/volume, HDL cholesterol, insulin sensitivity, and resting energy expenditure with no change in body weight or fat mass (O'Mara et al., J Clin Invest 2020, PMID 31961826)—an open-label study without placebo control. Rat studies confirmed selective β3-adrenoceptor agonist activity with bladder-relaxant effects (Hatanaka et al., 2013, PMID 23239087). Ex vivo porcine ureter studies found mirabegron reduced contractility partly via α1-adrenoceptor antagonism, complicating a pure β3-selectivity profile at the ureter (PMC9192402).
Meldonium and Mirabegron (YM-178) are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Dosing Notes
Side Effects
Contraindications
Lab Testing
Disclosed Labs